Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer

Shahab Akhoondi1,2, Linda Lindström2, Martin Widschwendter4, Martin Corcoran2, Jonas Bergh2,3, Charles Spruck5, Dan Grandér2, Olle Sangfelt1,2*

Abstract

Introduction: Mutational inactivation of the FBXW7/hCDC4 tumor suppressor gene (TSG) is common in many cancer types, but infrequent in breast cancers. This study investigates the presence and impact of FBXW7/hCDC4 promoter methylation in breast cancer.

Methods: FBXW7/hCDC4-β expression and promoter methylation was assessed in 161 tumors from two independent breast cancer cohorts. Associations between methylation status and clinicopathologic characteristics were assessed by Fisher’s exact test. Survival was analyzed using the Kaplan-Meier method in addition to modeling the risk by use of a multivariate proportional hazard (Cox) model adjusting for possible confounders of survival.

Results: Methylation of the promoter and loss of mRNA expression was found both in cell lines and primary tumors (43% and 51%, respectively). Using Cox modeling, a trend was found towards decreased hazard ratio (HR) for death in women with methylation of FBXW7/hCDC4-β in both cohorts (HR 0.53 (95% CI 0.23 to 1.23) and HR 0.50 (95% CI 0.23 to 1.08), respectively), despite an association between methylation and high-grade tumors (P = 0.017). Interestingly, in subgroups of patients whose tumors are p53 mutated or lymph-node positive, promoter methylation identified patients with significantly improved survival (P = 0.048 and P = 0.017, respectively).

Conclusions: We demonstrate an alternative mechanism for inactivation of the TSG FBXW7/hCDC4, namely promoter specific methylation. Importantly, in breast cancer, methylation of FBXW7/hCDC4-β is related to favorable prognosis despite its association with poorly differentiated tumors. Future work may define whether FBXW7/hCDC4 methylation is a biomarker of the response to chemotherapy and a target for epigenetic modulation therapy.

Introduction

The F-box protein Fbxw7/hCdc4 is the substrate specificity component of the SCFFbxw7/hCdc4 ubiquitin ligase. SCFFbxw7/hCdc4 is responsible for the targeted ubiquitylation and subsequent proteasomal degradation of an array of oncoproteins that plays a critical role in oncogenesis, such as cyclin E, c-Myc, Notch, and c-Jun among others [1,2]. Substrate recognition is tightly regulated by phosphorylation of specific motifs in the target proteins called Cdc4 phosphodegrons (CPDs) [3]. In line with its suppressive function on oncoproteins, SCFFbxw7/hCdc4 is inactivated by mutations in various tumor types [4]. The majority of the mutations identified in Fbxw7/hCdc4 in cancer specimens are missense mutations in the binding pocket of Fbxw7/hCdc4 that prevent its interaction with the phosphorylated CPD motif in the target proteins [4,5].

The tumor suppressor function of Fbxw7/hCdc4 is further underscored by frequent deletions of its locus at chromosome 4q31, occurring in more than 30% of all neoplasms [6]. Furthermore, targeted disruption of the Fbxw7/hCdc4 gene has been shown to result in enhanced genomic instability [7], a hallmark of cancer cells. Studies in mice additionally support a tumor suppressive activity of Fbxw7/hCdc4. Conditional inactivation of Fbxw7/hCdc4 in the T-cell lineage of mice...
promoted the development of thymic lymphomas [8] and loss of one Fbxw7/hCdc4 allele was shown to accelerate tumor development in p53-heterozygous (p53+/-) mice [9].

Little is known about the transcriptional regulation of Fbxw7/hCdc4, but it has been shown to be a target of p53 activation [10], establishing a direct link between these two tumor suppressor genes (TSGs).

Three different Fbxw7/hCdc4 isoforms (α, β and γ) have been identified in mammals [11]. Each isoform creates proteins with identical substrate interaction domains and a shared F-box motif linking to the common core ligase components (Skp1-Cul1-Roc1), but encode unique N-terminal regions that localize each isoform to specific subcellular compartments [1,2]. Each isoform is believed to possess its own promoter, which could be differentially regulated in a cell type-specific manner. Furthermore, isoform specific interactions with several accessory proteins have been reported [12,13]. Importantly, mutations in specific isoforms have also been identified in cancers, further strengthening the notion of non-redundant functions for the three different Fbxw7/hCdc4 isoforms [4,11,14].

Although mutations in Fbxw7/hCdc4 are frequent events in diverse tumor types, including endometrial carcinomas, cholangiocarcinomas, colorectal cancer and T-cell acute lymphoblastic leukemia [4,7,11,15,16], mutations are uncommon or absent in other malignancies [4,17]. Thus, alternative mechanisms for inactivation of Fbxw7/hCdc4 are likely to exist. Downregulation of Fbxw7/hCdc4 expression has been reported in glioma [18], gastric cancer [19] and colorectal [20], but the mechanism(s) responsible for loss of expression of Fbxw7/hCdc4 in cancer is not known.

Epigenetic inactivation of TSGs by promoter hypermethylation is a frequent event during tumorigenesis [21,22]. In breast cancer, the most common malignant disease in women, hypermethylation of specific genes has been associated with the response to therapy, prognosis, invasiveness and metastasis [23,24]. Hypermethylation of TSGs in breast cancer is often associated with clinicopathological factors predicting poor prognosis and consequently serves as potential therapeutic targets for demethylating agents. However, recent data also indicate that methylation of specific TSGs can predict sensitivity to chemotherapy thus opening up the potential for DNA methylation as a biomarker to further individualize cancer treatment in the future [25].

In the present study, we examined the possibility that Fbxw7/hCdc4 expression is epigenetically inactivated through promoter specific hypermethylation in breast cancer, a tumor type where Fbxw7/hCdc4 mutations are not commonly observed [4]. We also explored the possibility that aberrant promoter methylation associates with clinical parameters and overall survival in breast cancer. The results demonstrate that 51% of primary breast tumor specimens have a methylated Fbxw7/hCdc4 promoter with concomitant loss of Fbxw7/hCdc4 expression. Interestingly, although methylation associates with high-grade tumors, univariate and multivariate analysis suggest that Fbxw7/hCdc4 promoter methylation might be a favorable prognostic marker in breast cancer.

Materials and methods

Tumor specimens and clinicopathological features

A total of 161 primary breast tumor specimens from two breast cancer cohorts were included in this study. Among the 161 samples in which Fbxw7/hCdc4 promoter methylation was analysed, RNA was available from 139 samples, which was further processed for cDNA synthesis and Fbxw7/hCdc4 expression analysis as described below. A total of 68 cases of primary breast cancer were obtained from patients diagnosed at the Department of Obstetrics and Gynecology of the Innsbruck Medical University of Austria (cohort 1) and 93 samples were obtained from patients at the Department of Pathology of Uppsala University, Uppsala, Sweden (cohort 2). All patients underwent resection of the tumor during surgery and specimens were processed by pathologists at the affiliated hospital. Samples were snap frozen in liquid nitrogen and stored at -80°C until RNA and DNA extraction.

Cohort 1: Clinicopathologic features for this collection of samples have been previously reported [26]. Patients were diagnosed and operated on between 1990 and 2001 and the median age of the patients included in this study was 64 years (range 33 to 88). Patients were treated in compliance with the national recommendations at the time. Forty-one and 27 patients underwent a lumpectomy or a mastectomy, respectively. Thirty-eight patients received loco-regional radiation. Thirty-five patients received adjuvant combination chemotherapy CMF (cyclophosphamide, methotrexate and 5-fluorouracil), and 33 patients received adjuvant anti-hormonal therapy. All samples were collected during surgery in compliance with and approved by the Institutional Review Board and with informed consent from the patients. p53 was sequenced in tumor samples from cohort 1 using either genomic DNA or cDNA as a template with primers derived from intrinsic or gene specific sequences (primer sequences can be obtained from the authors upon request). PCR amplification and purification was performed as previously described [4,15] and sequenced at Eurofins MWG Operon (Eurofins MWG Operon, Ebersberg, Germany).

Cohort 2: Breast cancer patients were diagnosed and operated on between 1987 and 1989 at Uppsala...
University Hospital, Uppsala, Sweden. The median age for the patients used in this study was 63 years (range: 28 to 94). Clinicopathological data and treatment have been previously reported [27,28]. Briefly, patients were operated on and received postoperative radiotherapy. When adjuvant tamoxifen was given, some patients received this treatment as part of a randomized study comparing two versus five years, and chemotherapy, mostly CMF according to standards in those days [27,28]. Ethical permission was obtained from the ethical committee at Karolinska Institute and with informed consent from the patients. Data on p53 mutational status in this series of breast tumor specimens have been described [27].

Genomic DNA and RNA from fresh frozen tumor tissue were isolated as previously described [4,15]. RNA from various normal tissues was purchased from ABI (Applied Biosystems, Foster city, CA, USA). Normal breast tissue was obtained from reduction surgeries as well as from noncancerous tissue DNA extracted from paraffin-embedded breast cancer specimens. cDNA was synthesized from 2 μg of total RNA using Superscript First-strand Synthesis System (Invitrogen, Carlsbad, CA, USA).

**Cell lines, transfections and treatments**

A total of 60 human cancer cell lines, originating from breast, brain, prostate, kidney, blood, cervix, lung, skin, bone and thyroid (See Additional file 1 for details), were analyzed for FBXW7/hCDC4 expression and promoter methylation. Cell lines were maintained and cultured according to American Type Culture Collection (ATCC) guidelines or as previously described [15,29]. All plasmid transfections were performed using LT1 transfection reagent (MIRUS, Madison, WI, USA), as recommended by the manufacturer’s protocol. For experiments evaluating the effects of demethylation, cell lines maintained in appropriate media were treated with 5-aza-2′-deoxycytidine (5-aza-dC) (Sigma-Aldrich, St Louis, MO, USA) or DMSO for three to five days.

**Cloning**

A 1.6 kb genomic region (-1293 bp to +309 bp from the transcription start site (TSS)) of the FBXW7/hCDC4-β isoform containing 18 CpG sites was amplified by PCR, cloned into the pSC-A vector (Stratagene, Santa Clara, CA, USA) and sequenced. The specific primers used for amplification of the FBXW7/hCDC4-β promoter, were as follows; FP1: 5′-GCC ATT TAC CAT AGC AGA GAG TA-3′, RP1: 5′-GCT ATG TGA TGT TGT GTG TAT GCC-3′. Two shorter versions of the promoter, containing 11 and 6 CpGs respectively, were also amplified using the following forward primers, FP2: 5′-AGA CTT ATT TGT GGA AAT GTT CCT TGC TA or FP3: 5′-GCA TTG CTG AAT CCT GGA CTG CAC C and the reverse primer, RP1. Each promoter region was subclone into pGL3 vector (Promega, Madison, WI, USA) after KpnI and BglII restriction digestion (New England Biolabs, Ipswich, MA, USA). The resulting promoter constructs were termed pGL3hCDC4-β-1.6, pGL3hCDC4-β-0.8. and pGL3hCDC4-β-0.6. The pRL-SV40 Renilla luciferase plasmid was obtained from Promega (Madison). PCR reactions were performed in a BioRad thermocycler (Techne, Burlington, NJ, USA).

**Luciferase assay**

Luciferase activities in cell lysates from cells transfected with different pGL3 constructs and pRL-SV40 control plasmid were measured in a luminometer (VICTOR3, PerkinElmer, Waltham, MA, USA) using the Dual-Luciferase Reporter Assay System according to the manufacturer’s protocol (Promega). Luciferase activities were quantified and fold change was averaged from at least three separate experiments performed in triplicates.

**DNA methylation analysis**

Methylation of the FBXW7/hCDC4-β promoter was examined in cell lines, normal breast and primary tumors by several methods. Bisulfite-modified genomic DNA was prepared and CpG methylation was analysed by bisulfite-sequence analysis as previously described [30,31]. The methylation status of the complete FBXW7/hCDC4-β promoter was determined by sequence analysis of at least five individual clones from cell lines if not otherwise stated. For screening of relative methylation levels, the McrBc restriction enzyme (New England Biolabs) was used. McrBc recognize and cuts pairs of purine-methyl cytosines (recognition sequence RmC(N)55-103RmC) and subsequent PCR amplification of methylated DNA segments in comparison with an unmethylated segments thus denotes the methylation status of the region of interest. Briefly, 200 ng of genomic DNA was treated with or without 0.5 unit of McrBc enzyme for 1 hr at 37°C in the reaction buffer provided by the supplier. Each sample was heat inactivated and subsequently amplified by PCR using FP1 and RP1 primers. PCR amplification was performed with 100 ng DNA as template in the following conditions; two minutes denaturation and 30 cycles of amplification (94°C for 30 s, 64°C for 30 s, and 68°C for one minute) using Titanium Taq DNA polymerase (BD) (Becton dickinson, Franklin Lakes, NJ, USA). PCR products were resolved on agarose gels and band intensities were quantified by Image J software (Image), U. S. National Institutes of Health, Bethesda, Maryland, USA) [32] The mean McrBc ratio (band intensity of McrBc digested DNA divided by undigested DNA) in unmethylated DNA samples obtained from normal breast tissue and
tumor-derived cell lines (verified through bisulfite sequence analysis) was 0.808 with a standard deviation (SD) of 0.11. Test samples were judged as methylated if their McrBc ratio had a decreased value greater than 2 SD as compared to the unmethylated control samples. A McrBc methylation ratio of 0.6 was thus used as a cutoff. The McrBc results were also confirmed by restriction digestion of PCR products using Taq I and HpyCHIV enzymes (cuts methylated CG11 and CG18, respectively, data not shown). To verify the effect of promoter methylation on FBXW7/hCDC4-β expression, luciferase reporter constructs were methylated in vitro with Sss I methylase (New England Biolabs) as previously described [33]. Screening for methylation of their McrBc ratio had a decreased value greater than 2 SD as compared to the unmethylated control samples. A McrBc methylation ratio of 0.6 was thus used as a cutoff. The McrBc results were also confirmed by restriction digestion of PCR products using Taq I and HpyCHIV enzymes (cuts methylated CG11 and CG18, respectively, data not shown).

### Expression analysis

FBXW7/hCDC4 isomorph-specific primers and TaqMan probes for quantitative real-time PCR analysis of different FBXW7/hCDC4 isoforms have been described [12]. The ΔΔCt method of relative quantification was performed to determine relative mRNA expression in each sample. The relative expression level of each FBXW7/hCDC4 isoform was obtained by normalizing the expression of FBXW7/hCDC4 mRNA to GAPDH mRNA expression. Primers and conditions for semi-quantitative RT-PCR of FBXW7/hCDC4 isoforms have been described [29]. Amplification of GAPDH mRNA served as an internal control. Oestrogen and progesterone receptor (ER/PR) status was determined by immunohistochemistry as previously described [34].

### Statistical analysis

The association between patient clinicopathological characteristics (such as oestrogen receptor, progesterone receptor, lymph node involvement, grade, stage and age) and methylation status of the FBXW7/hCDC4-β isoform, in addition to P53 mutation, was determined using the Fisher’s exact test. Differences in FBXW7/hCDC4-β expression between methylated and unmethylated groups were analysed by means of the (non-parametric) Wilcoxon-Mann-Whitney test. Univariate analyses of survival were conducted by use of the Kaplan-Meier method. Further, the risk of dying in women with methylation of the FBXW7/hCDC4-β isoform compared with women with unmethylated FBXW7/hCDC4-β isoform was modelled by use of multivariable proportional hazards (Cox) models, adjusted for possible confounders of survival such as age at diagnosis, date of primary tumour surgery, oestrogen receptor and progesterone receptor status, and P53 mutation. An arbitrary level of 5% statistical significance was used. Finally, data preparation and analysis was done using the SAS Statistical package, version 9.2 (SAS Institute Inc., Cary, NC, USA).

### Results

#### Identification of promoter methylation and loss of FBXW7/hCDC4-β expression in tumor cell lines

Mammals express three Fbxw7/hCdc4 splice variants designated α, β, and γ, each encoding a unique N-terminal protein sequence fused to 10 downstream exons, suggesting non-redundant functions as mentioned above. Semi-quantitative RT-PCR analysis of the different FBXW7/hCDC4 isoforms revealed substantial differential expression of the FBXW7/hCDC4-β transcript in specific cell lines from various tumor tissues (Figure 1a). The immortalized breast epithelial cell lines IME and MCF10, expressed high levels of FBXW7/hCDC4-β compared to some breast cancer cell lines with low or absent FBXW7/hCDC4-β expression (Figure 1a, left). This variation in mRNA expression was not generally observed for the FBXW7/hCDC4-α isoform, which was the most abundant and ubiquitously expressed FBXW7/hCDC4 transcript in most cell lines examined (Figure 1a).

As previously reported [35,36], the beta isoform was expressed at very high levels in tissue from normal brain (Figure S1 in Additional file 1). Significant expression was also observed in tissues from normal breast, ovary and cervix, compared to other tissues with low (spleen, thyroid, liver) or absent (skeletal muscle) FBXW7/hCDC4-β expression (Figure S1 in Additional file 1). To examine whether loss of FBXW7/hCDC4-β expression correlated with hypermethylation of its promoter, we first examined the sequence 1.3 kb upstream and 0.3 kb downstream of the transcription initiation start site in FBXW7/hCDC4-β. Eighteen CpG sites were distributed throughout this region (Figure 1b). To this end, we used bisulfite sequence analysis to determine the methylation status of each of these CpGs in five different cell lines with low/absent FBXW7/hCDC4-β expression (HeLa, U266, PEER, Daudi and DLD1) and five cell lines with high expression (IME, MB-468, T-ALL, 293A and MOLT4). Regarding the methylation status, cell lines were found to fall into two distinct groups; one demonstrating methylation of the majority of CpGs (90 to 100%) correlating with low expression, and the other exhibiting mostly unmethylated CpGs and showing high expression (Figure 1c). Screening for methylation was also carried out using the restriction enzyme McrBc, a methylation specific endonuclease, which cuts DNA containing 5-methylcytosine in the context of a second, arbitrarily spaced methylcytosine, and does not cleave unmethylated DNA. As shown in Figure 1d, screening...
for methylation of this region with the McrBc enzyme recapitulated the methylation results obtained by bisulfate sequence analysis.

Assessing methylation by McrBc digestion in 50 additional cell lines from various tissues (Table S1 in Additional file 2) demonstrated methylation in 26 of 60 (43%). FBXW7/hCDC4-β expression was next analyzed by real time reverse transcription PCR. A significant difference in expression between methylated and unmethylated cell lines (Figure 2a, \( P = 0.0001 \)) was found with lower expression in methylated (median expression = 0.02, range: 0 to 0.9) compared to unmethylated cell lines (median expression = 1.6, range: 0 to 8.1). No correlation between methylation of the \( FBXW7/hCDC4-\beta \) promoter and expression of \( FBXW7/hCDC4-\alpha \) mRNA was found (data not shown).

To establish a direct link between methylation and silencing of \( FBXW7/hCDC4-\beta \) expression we treated HeLa, BT-20, U2OS and BT-474 cells with the DNA methylation inhibitor 5-aza-dC. As can be seen in Figure 2b, 5-aza-dC treatment increased \( FBXW7/hCDC4-\beta \) mRNA expression levels in methylated cell lines (HeLa and BT-20), with an initial low expression, in contrast to the unchanged high \( FBXW7/hCDC4-\beta \) levels of unmethylated cell lines (U2OS and BT-474) (Figure S2A in Additional file 3). Demethylation of the promoter upon 5-aza-dC treatment was confirmed by McrBc digestion (Figure 2c) and sequencing of bisulfite treated DNA.

Figure 1 Differential expression of \( FBXW7/hCDC4-\beta \) mRNA and promoter methylation in tumor cell lines (a) Semi-quantitative RT-PCR analysis of \( FBXW7/hCDC4 \) isoforms, left, in normal breast, immortalized mammary epithelial cells and breast cancer cell lines, right, in human cancer lines from different origins. GAPDH was amplified as an internal control. (b) Schematic map of the \( FBXW7/hCDC4-\beta \) promoter region around the transcription start site (TSS). CpG dinucleotides are depicted. PCR primers used for amplification of the promoter are indicated as arrows (FP1 and RP1). The translational start codon (ATG), centromere (Cen) and telomere (Tel) are marked. (c) real-time PCR showing the relationship between \( FBXW7/hCDC4-\beta \) expression (top) and promoter methylation (bottom); Methylation is presented as the percentage of methylated CpG sites based on bisulfite sequence analysis of genomic DNA from different cancer cell lines. The degrees of methylated cytosines or unmethylated cytosines are indicated by black or white boxes, respectively. (d) Representative gel analysis of PCR product (1.6 kb) from McrBc digested (+) genomic DNA in comparison with undigested (-) control DNA. Note the lack of amplification of McrBc digested DNA from methylated cell lines (HeLa and DLD1) in comparison to unmethylated cell lines (IME and T-ALL).
As a control, FBXW7/hCDC4-a mRNA expression was measured after 5-aza-dC treatment. No significant increase of FBXW7/hCDC4-a levels was observed in any of the cell lines examined (Figure S2B in Additional file 4 and data not shown).

To confirm that the FBXW7/hCDC4-β promoter region possesses transcriptional activity, we performed luciferase reporter assays with the 1.6 kb genomic region covering all 18 CpGs (Figure 1b) and two shorter promoter regions (0.8 and 0.6 kb), being deletion constructs of the 1.6 kb region mentioned above. Robust reporter activity was observed in cell lines of different origins with all three constructs, albeit a reduced activity was observed with the shorter promoter constructs (data not shown). To further evaluate the effect of methylation on promoter activity, we next performed reporter assays using transient transfection of constructs where the FBXW7/hCDC4-β promoter was methylated in vitro using the SsI methylase as previously described [33]. As shown in Figure 2d, in vitro methylation suppressed reporter activity confirming that methylation of the promoter abrogates FBXW7/hCDC4-β expression.

Together, these data demonstrate that CpG-methylation correlates with loss of FBXW7/hCDC4-β expression in tumor cell lines. These data also indicate that methylation could be a significant factor in regulating FBXW7/hCDC4-β expression in some malignancies, including breast cancer.

**FBXW7/hCDC4-β promoter methylation in primary breast cancer specimens**

Based on the results above, we next explored the occurrence and role of FBXW7/hCDC4-β methylation in primary breast cancer specimens. To exclude the possibility that methylation detection is affected by contaminating noncancerous cells, we first analysed FBXW7/hCDC4-β
promoter methylation in normal breast tissues (obtained from normal breast reductions) by McrBc digestion (Figure 3a) and bisulfite sequence analysis (data not shown). Importantly, methylation was absent in normal breast tissues as well as in noncancerous tissue DNA extracted from a paraffin-embedded breast cancer specimen (Figure 3a and data not shown). We next analyzed FBXW7/hCDC4 mRNA expression in two cohorts of breast cancer specimens in which RNA was available and FBXW7/hCDC4 mRNA expression could be analysed. A total of 71 out of 139 (51%) patient samples showed methylation of the promoter as defined by McrBc digestion, compared to its undigested control (Figure 3a). Tumor specimens were classified as low or high methylation (see Materials and methods for details on quantification and classification of promoter methylation), divided into two groups and compared with the mRNA expression levels of FBXW7/hCDC4. Similar to the results in tumor cell lines, a statistically significant difference was found between the groups (Figure 3b, P = 0.0002). The methylated group showed significantly lower expression of FBXW7/hCDC4 (median expression = 0.13, range; 0 to 1.43) as compared to the unmethylated group, which had higher expression levels (median expression = 0.30, range; 0 to 8.83).

The results demonstrate that there is a significant inverse correlation between promoter methylation and FBXW7/hCDC4 expression in primary breast cancer specimens.
Table 1 Association of FBXW7/hCDC4-β promoter methylation in 161 primary breast cancer patients with clinicopathological features

| Clinicopathological Features | UM (%) | M (%) | P  |
|-----------------------------|--------|-------|----|
| Age                         |        |       |    |
| ≤67                         | 37 (45.1) | 45 (54.9) | 0.27 |
| >67                         | 43 (54.4) | 36 (45.6) |    |
| ER                          |        |       |    |
| Negative                    | 17 (37.7) | 28 (62.3) | 0.08 |
| Positive                    | 61 (54) | 52 (46) |    |
| Unknown                     | 2 (1)   | 1     |    |
| PR                          |        |       |    |
| Negative                    | 17 (40) | 25 (60) | 0.21 |
| Positive                    | 61 (52.5) | 55 (47.5) |    |
| Unknown                     | 2 (1)   | 1     |    |
| LN                          |        |       |    |
| Negative                    | 41 (50.6) | 40 (49.4) | 0.75 |
| Positive                    | 36 (47) | 40 (53) |    |
| Unknown                     | 3 (1)   | 1     |    |
| Grade                       |        |       |    |
| I/II                        | 64 (55.1) | 52 (44.9) | 0.017 |
| III                         | 13 (32.5) | 27 (67.5) |    |
| Unknown                     | 3 (2)   | 2     |    |
| Stage                       |        |       |    |
| I/II                        | 58 (52.2) | 53 (47.8) | 0.18 |
| III                         | 9 (36) | 16 (64) |    |
| Unknown                     | 12 (12) | 12 (12) |    |

* Fisher’s exact test. UM, unmethylated; M, methylated; ER, estrogen receptor; PR, progesterone receptor; LN, lymph node.

Correlation of FBXW7/hCDC4-β methylation with clinicopathological characteristics

Data on methylation status and clinicopathological parameters were available for a total of 161 tumor specimens (68 cases from cohort 1 and 93 cases from cohort 2). The associations between FBXW7/hCDC4-β methylation and clinicopathological features are summarized in Table 1. Methylation was significantly associated with high-grade tumors (P = 0.017) and a trend towards an association with estrogen receptor-negative tumors was also observed in the methylated group (Table 1). No significant associations were observed between methylation of FBXW7/hCDC4-β with age, stage and lymph node status (Table 1) or with p53 mutational status (Table S2 in Additional file 5). As previously reported [27], p53 mutation was associated with high-grade and receptor-negative (ER and PR) tumors (Table S2 in Additional file 5).

Correlation of FBXW7/hCDC4-β methylation and prognosis

To evaluate whether methylation of FBXW7/hCDC4-β was an independent prognostic factor in breast cancer, we examined the significance of methylation using multivariate analysis, including adjustment for other factors known to be associated with clinical outcome. As the cohorts from the two centers were treated during different time periods, and thus partly using different treatment protocols, this outcome analysis was performed separately for the two groups. This also enabled a validation of the findings in the two independent cohorts. In both cohorts, methylation of FBXW7/hCDC4-β was found to be associated with an approximately 50% decreased risk of death (cohort 1 hazard ratio 0.53 (0.23 to 1.23) and cohort 2 (HR) 0.50 (95% CI 0.23 to 1.08), Table 2). We also performed log rank analysis of Kaplan-Meier curves for overall survival in defined prognostic subgroups. Methylation was associated with a significantly improved overall survival in patients with lymph node metastasis, in cohort 1 (Figure 4a, P = 0.017). In this cohort, patients with ER receptor-negative tumors additionally demonstrated a clear trend, although not statistically significant (P = 0.111, data not shown), for improved survival in methylated tumors. In line with the data from cohort 1, the overall survival in women with lymph node-positive tumors from cohort 2 was higher in the group whose tumors demonstrated a methylated FBXW7/hCDC4-β promoter, compared to women with an unmethylated promoter (Figure 4b). However, this difference was not statistically significant, possibly due to the smaller number of patients in this subgroup from cohort 2 (n = 35 out of 93), in comparison with cohort 1 (n = 41 out 68). No clear conclusions could be drawn from cohort 2 regarding the prognostic significance for FBXW7/hCDC4-β methylation in the ER-negative group, due to the limited number of patients (n = 13). Methylation was also associated with a significantly improved overall survival in the p53 mutated subgroup in cohort 2 (Figure 4c, P = 0.048). Thus, in two subgroups with known adverse prognostic features (that is, patients with lymph node metastasis and patients whose tumors harbored p53 mutation) FBXW7/hCDC4-β methylation was found to be associated with improved survival. No association between survival and methylation of FBXW7/hCDC4-β was found to be associated with improved survival. No association between survival and methylation of FBXW7/hCDC4-β was

Table 2 Methylation status and overall survival in primary breast cancer patients using Cox proportional hazard model

| Cohort | Patients | (%) | Deaths | HR | 95% CI* | P  |
|--------|----------|-----|--------|----|---------|----|
| 1      | UM       | 30  | 14     | 1.0 (ref) |       |
|        | M        | 38  | 12     | 1.0 (ref) |       |
| 2      | UM       | 50  | 21     | 1.0 (ref) |       |
|        | M        | 43  | 28     | 1.0 (ref) |       |

* Cohort 1 (n = 68) and Cohort 2 (n = 93).

* Adjusted for age, period of diagnosis, ER, PR and p53 status. HR, hazard ratio; UM, unmethylated; M, methylated.
found in patients with lymph node negative tumors (Figure S3 in Additional file 6). No clear conclusions could be drawn from cohort 1 regarding the prognostic significance for patients with p53 mutation and FBXW7/hCDC4β methylation due to the limited number of patients and events in the p53 mutated/FBXW7/hCDC4β methylated subgroup.

Discussion

F-box proteins are substrate recognition subunits of the SCF ubiquitin ligases with well-established functions in cell cycle control and tumor development [37,38]. We recently performed a comprehensive analysis of primary human tumors and showed mutations in the F-box gene FBXW7/hCDC4β to occur with an overall frequency of 6% in diverse tumor types [4]. FBXW7/hCDC4β mutations were first identified in breast cancer and ovarian cell lines [14,35]. However, analysis of more than 151 primary breast tumor specimens showed that FBXW7/hCDC4β mutations are rare in this malignancy [4]. Several studies have reported reduction in FBXW7/hCDC4 copy number due to deletion of chromosome 4q [6,39]. However, loss of FBXW7/hCDC4 expression in cancer can occur without genetic alteration [20], implicating a possible role for epigenetic silencing of FBXW7/hCDC4.
In this study, we report for the first time promoter specific methylation of the FBXW7/hCDC4-β isoform in primary breast tumors. Two independent cohorts of primary breast tumors were analyzed and promoter hyper-methylation was found to correlate with downregulation of FBXW7/hCDC4-β mRNA expression (Figure 3b). Moreover, using DNA methylation inhibitors in intact cells as well as in vitro methylation of promoter constructs in reporter assays, we demonstrate that FBXW7/hCDC4-β expression is regulated by promoter hyper-methylation (Figure 2). Loss of FBXW7/hCDC4 expression is unlikely to result from allelic imbalances of the 4q31 locus, as examination of >140 primary breast tumors using Representational Oligonucleotide Microarray Analysis (ROMA [40]), showed that FBXW7/hCDC4 is hemizygously deleted in less than 20% of primary breast tumors (data not shown, A. Zetterberg and P. Lundin, personal communication).

In breast cancer ER/PR and HER-2/neu represent the few established molecular markers used both for prognostication as well as to predict the response to tamoxifen and herceptin, respectively [41,42]. Aberrant DNA methylation is a common event in cancer and a wealth of recent data indicates that altered methylation of TSGs in breast cancer is frequent, and that determination of such events can provide prognostic as well as predictive information [23,24,43]. However, there is still an urgent need for discovery of novel prognostic factors and predictive biomarkers that give pre-treatment information on the efficacy of adjuvant chemotherapy, which is commonly applied to many patients with primary breast cancer.

Methylation of TSGs often associates with adverse clinical factors [44-46]. In line with this, in this study, FBXW7/hCDC4-β promoter methylation significantly was associated with high-grade tumors and also occurred frequently in ER-negative tumors (Table 1). Interestingly, despite this, multivariate survival analysis demonstrated an association between methylation of FBXW7/hCDC4-β and decreased risk of death (Table 2). As mentioned above, the differences between the cohorts prohibited us from combining the data. It will thus be important to validate these findings in larger clinical cohorts.

Interestingly, sub-group analysis revealed that FBXW7/hCDC4-β methylation identifies patients with a significantly improved prognosis among patients whose tumors demonstrated the adverse features of lymph node metastasis and p53 mutation, respectively (Figure 4). This somewhat parallels previous findings from our group [15] and others [47] in T-cell acute lymphocytic leukemia (T-ALL), an ALL sub-group with relatively poor prognosis. In this malignancy, mutational inactivation of FBXW7/hCDC4 in combination with NOTCH1 mutations predicts a favorable outcome [15,47].

One may speculate why methylation of FBXW7/hCDC4-β in breast cancer associates with improved outcome. One reason may be that methylated tumors have a biologically less aggressive behavior. This seems less likely, in light of our findings that these tumors are overrepresented in subgroups of patients with high-grade tumors, and possibly ER-negativity. In line with this, we have preliminary data demonstrating an association between FBXW7/hCDC4-β methylation and high expression of the proliferation marker PCNA in breast cancer (correlation coefficient r = 0.313, P = 0.022 (n = 52, cohort 1)). Thus, a more likely possibility is that tumors with inactivated FBXW7/hCDC4-β may be more responsive to the given adjuvant treatment. This could also explain the greater impact of FBXW7/hCDC4-β methylation on survival in cohort 1, compared to cohort 2, as a higher proportion of patients in cohort 1 were exposed to adjuvant polychemotherapy (see materials and methods and 27). Furthermore, a link between FBXW7/hCDC4-β methylation and a tendency for increased survival was found in patients receiving chemotherapy and/or irradiation (Table S3 in Additional file 7), as analyzed in cohort 1.

FBXW7/hCDC4 function has been directly linked to cell cycle checkpoint controls, its inactivation resulting in improper M phase progression, formation of micronuclei and chromosomal instability [7]. Indeed, Finkin et al. hypothesized that loss of FBXW7/hCDC4 might have important effects on how cells respond to chemotherapeutic drugs, and showed that exposure of cells lacking FBXW7/hCDC4 to spindle toxins, such as taxol, commonly used in breast cancer treatment, renders cells more susceptible to endoreduplication and polyploidy [48].

The recent advances and understanding of how cell cycle checkpoints and DNA repair pathways respond to chemotherapy-induced DNA damage has opened up unprecedented opportunities for improved development of personalized treatment [49]. This is for instance exemplified in a recent elegant study that demonstrated a synthetic lethal interaction between ATM and p53 in response to cytotoxic drugs [50]. Remarkably, tumors defective for both ATM and p53 were more prone to drug induced cell killing and tumors with functional ATM but non-functional p53 could be sensitized by pharmacologic suppression of ATM signaling [50,51]. Similar results have been reported for other TSGs involved in controlling genomic stability, such as the inhibition of PARP-1 in BRCA1/2 deficient breast and ovarian tumors which selectively kills the cancer cells while sparing normal cells with a functional repair pathway [52]. Together, these findings highlight the importance for a detailed knowledge of genetic defects in tumors to identify those patients who will most likely respond to specific genotoxic drugs.
To date, defined Fbxw7/hCdc4 substrates are nuclear proteins (that is, C-Myc, cyclin E) degraded by the Fbxw7/hCdc4-α and/or Fbxw7/hCdc4-γ isoforms [1,2], whereas Fbxw7/hCdc4-β specific substrates still await discovery. Fbxw7/hCdc4-β localizes to the cytoplasm and could potentially target a pro-apoptotic substrate(s) or a protein(s) involved in DNA damage signaling that when stabilized sensitize tumor cells to chemotherapeutic drugs. Interestingly, Mao et al. recently reported that Fbxw7/hCdc4 targets the mammalian target of rapamycin (mTOR) for degradation [53]. The Fbxw7/hCdc4 isoform responsible for mTOR degradation was not defined in this study, but it’s noteworthy that mTOR localizes to the cytosol and that breast cancer cells with loss of Fbxw7/hCdc4 were shown to be more sensitive to mTOR inhibitors [53].

We have just begun to understand the complex interplay between FBXW7/hCDC4, its target oncoproteins and other critical cancer genes. For example, p53 is a direct transcriptional regulator of FBXW7/hCDC4 expression [10]. However, the functional relationship between these TSGs is still unclear and FBXW7/hCDC4 has also been suggested to act upstream of p53 [48]. Furthermore, a differential relationship with the various FBXW7/hCDC4 isoforms is possible. A recent study in gastric cancer revealed that patient samples with p53 mutations had lower FBXW7/hCDC4-α mRNA levels and those patients also had a poor prognosis compared with the other subgroups [19]. In line with these data, in our analysis of breast cancer specimens, we also found a statistically significant correlation ($P = 0.0002$) between low FBXW7/hCDC4-α expression and p53 mutation. To exclude the possibility that downregulation of FBXW7/hCDC4-α expression is due to promoter methylation, we have analysed the FBXW7/hCDC4-α CpG island for methylation. Methylation was not observed in any of the primary breast tumor specimens analysed, independently of FBXW7/hCDC4-α mRNA levels, indicating that p53 mutational status is major decisive factor in the regulation of FBXW7/hCDC4-α expression in breast cancer (manuscript in preparation). Interestingly, no significant association between the expression (or methylation) of FBXW7/hCDC4-β and p53 mutational status (Table S2 in Additional file 5 and data not shown) was found, and as mentioned above, methylation and loss of expression of FBXW7/hCDC4-β was instead linked to increased survival in the p53 mutated group. Thus, although FBXW7/hCDC4-β is a known transcriptional target of p53 [10], methylation of the promoter likely predominates in transcriptional suppression of FBXW7/hCDC4-β mRNA expression. In summary, we have identified a previously not recognized mechanism for inactivation of FBXW7/hCDC4 expression, namely promoter specific methylation with potential prognostic significance in breast cancer. These data suggest that methylation of the FBXW7/hCDC4-β promoter predicts a favorable prognosis in breast cancer, particular in specific patient subgroups, despite the association of FBXW7/hCDC4-β methylation with adverse clinical parameters. Further studies will be required to validate whether FBXW7/hCDC4-β methylation could serve as a biomarker for sensitivity to chemotherapy in breast cancer.

Conclusions

This study provides new insights into the causes and consequences of FBXW7/hCDC4 inactivation in breast cancer. The FBXW7/hCDC4-β promoter is methylated in approximately 50% of primary breast tumors and methylation correlates with loss of FBXW7/hCDC4-β expression. Furthermore, promoter methylation predicts a favorable prognosis in breast cancer, particularly in specific patient subgroups, despite the association of FBXW7/hCDC4-β methylation with adverse clinical parameters. The role of FBXW7/hCDC4-β methylation in breast cancer progression and its potential function as a novel biomarker for sensitivity to chemotherapy in breast cancer needs further investigation.

Additional material

Additional file 1: Supplemental Figure S1. FBXW7/hCDC4-β expression levels were examined by real-time PCR (and normalized to GAPDH mRNA levels) in a panel of different normal tissues. FBXW7/hCDC4-β was differentially expressed between tissues, with the highest expression in brain and moderate expression in cervix, ovary and breast. Low or no detectable expression was found in spleen, thyroid, liver and skeletal muscle, respectively.

Additional file 2: Supplemental Table S1. Panel of cell lines analyzed for FBXW7/hCDC4-β promoter methylation and expression.

Additional file 3: Supplemental Figure S2A. FBXW7/hCDC4-β expression levels in unmethylated cell lines BT-474 and U2OS after 5-aza-dC treatment. Mean ± SD.

Additional file 4: Supplemental Figure S2B. FBXW7/hCDC4-α expression levels in methylated cell lines HeLa and BT-20 after 5-aza-dC treatment. Mean ± SD.

Additional file 5: Supplemental Table S2. Association of p53 mutation, clinicopathological features and FBXW7/hCDC4-β methylation in primary breast cancer patients.

Additional file 6: Supplemental Figure S3. Kaplan-Meier analysis of overall survival in lymph node negative patients from cohort 1 and cohort 2.

Additional file 7: Supplemental Table S3. Association between FBXW7/hCDC4-β methylation status and treatment outcome in breast cancer patients (cohort 1).

Abbreviations

CPD: CDC4 phosphodegron; ER: estrogen receptor; HR: hazard ratio; LN: lymph node; M: methylated; PCR: polymerase chain reaction; PR: progesterone receptor; RT-PCR: quantitative real-time PCR; RT: reverse transcriptase PCR; SCF: (SKP1/CUL1/F-box); SD: standard deviation; TSG: tumor suppressor gene; UM: unmethylated.
Acknowledgements
We thank Bert Vogelstein (John’s Hopkins University, Baltimore, MD, and Howard Hughes Medical Institute, Chevy Chase, MD) for HCT-116 and DLD1 wild-type and Fbxw7/hCDC4-/- cell lines, Olle Larsson and Monica Nisetér at the Cancer Center Karolinska (CKC), for providing tumour cell lines. We acknowledge Dr. Alena Malyukova for support and technical assistance.

Grant support: S. Akhoondi is an MD and Scholar in experimental oncology funded by the Cancer Society in Stockholm. This work was also supported by grants from the Swedish Cancer Society (O.S., DG, JB), the Swedish Research Council (OS, DG, JB, the Cancer Society in Stockholm (OS, JB), the Gustaf V Jubilee Foundation (DG, JB), the Swedish Breast Cancer Group (JB), ALF/FOU (JB), Stockholm County Council (JB), Linné Foundation (JB), Marit & Hans Rausing initiative against Breast Cancer (JB), and the Department of Defense Breast Cancer Research Program (DOD BCRP) (CS). Part of this work has been undertaken at UCLH/UCL who received a proportion of funding from the Department of Health NIHR Biomedical Research Centres funding scheme (MW).

Author details
Departments of Cell and Molecular Biology, Karolinska Institute, Berzelius vág 35, Box 285 S-17177, Stockholm, Sweden. Departments of Oncology-Pathology, Cancer Center Karolinska, Radhushemmet, Karolinska Institute and Hospital, S-17176, Stockholm, Sweden. Department of Medical Oncology, Christie Hospital, Manchester University and Christie Hospital, Wilmslow Road, Manchester, M20 4BX, UK. Department of Gynecological Oncology, Institute for Women’s Health, University College London, EGA Hospital, 2nd Floor Huntley Street, London, WC1E 6DH, UK. Sanford-Burnham Medical Research Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA.

Authors’ contributions
SA performed laboratory experiments, data analysis and wrote the manuscript. MG assisted in methylation analysis. OS, SA and DG initiated and designed the study. OS, DG, CS and JB were involved in experimental design and preparation of the manuscript. JB and MW were responsible for the patient cohorts. LL, MW and SA performed statistical analyses. All authors have read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 27 August 2010 Revised: 5 November 2010 Accepted: 1 December 2010 Published: 1 December 2010

References
1. Tan Y, Sangfelt O, Spruck C. The Fbxw7/hCDC4 tumor suppressor in human cancer. Cancer Lett 2008, 271:1-12.
2. Weikler M, Clurman BE. Fbxw7 ubiquitin ligase: a tumor suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 2008, 8:83-93.
3. Ollivody S, Tang X, Willems A, Tyers M, Sicheri F. Structural basis for phosphodependent substrate selection and orientation by the SCF/hCDC4 ubiquitin ligase. Cell 2003, 112:243-256.
4. Akhoondi S, Sun D, von der Lehr N, Akhoondi S, Corcoran M, Heyman M, Spruck C, Giardini D, Lendahl U, Sangfelt O, Spruck C. Fbxw7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res 2007, 67:9006-9012.
5. Hao B, Oehlmann S, Sowa ME, Harper JW. Pavletich NP Structure of a Fbxw7-5kπ-cyclin E complex: multisite-phosphorylated substrate recognition by SCF ubiquitin ligases. Mol Cell 2007, 26:131-142.
6. Knuttila S, Aalto Y, Auto K, Bjorkqvist AM, El-Rifai W, Hemmings S, Huhta T, Kettunen E, Kuru-Kuhielä E, Laramendi M, Lushnikova T, Monni O, Dere H, Tapper J, Tarkanen M, Varis A, Wasienski VM, Wolf M, Zhu Y. DNA copy number losses in human neoplasms. Am J Pathol 1999, 155:683-694.
7. Rajagopalan H, Jallepalli PV, Rago C, Velculescu VE, Kindler KW, Vogelstein B, Lengauer C. Inactivation of hCDC4 can cause chromosomal instability. Nature 2004, 428:77-81.
8. Matsuoka S, Oike Y, Onoyma I, Iwama A, Ari F, Takubo K, Mashimo Y, Oguro H, Nitta E, Ito K, Miyamoto K, Yoshihara H, Hosokawa K, Nakamura Y, Gomei Y, Iwasaki H, Hayashi Y, Matsuzaki Y, Nakayama KI, Ikeda Y, Hata A, Chiba S, Nakayama KI, Suda T. Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL. Genes Dev 2008, 22:986-991.
9. Mao JH, Perez-Lozada I, Wu D, Delrosario R, Tsunematsu R, Nakayama KI, Brown K, Bryson S, Balmain A. Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumor suppressor gene. Nature 2004, 432:775-779.
10. Kimura T, Gotot M, Nakamura Y, Arakawa H. HNCD4b, a regulator of cyclin E, as a direct transcriptional target of p53. Cancer Sci 2003, 94:431-436.
11. Spruck CH, Strohmaier H, Sangfelt O, Müller HM, Hubalek M, Müller-Holzner E, Marsh C, Widischwender M, Reed SI. HCD4e gene mutations in endometrial cancer. Cancer Res 2002, 62:4535-4539.
12. van Drogen F, Sangfelt O, Malyukova A, Matsioka L, Yeh E, Means AR, Reed SI. Ubiquitylation of cyclin E requires the sequential functional of SFC complexes containing distinct hCDC4 isoforms. Mol Cell 2006, 23:37-48.
13. Popov N, Herold S, Llamazares M, Schulein M, Eilers M Fbw7 and Usp28 regulate myc protein stability in response to DNA damage. Cell Cycle 2007, 6:2327-2331.
14. Moberg KH, Bell DW, Wahner DC, Haber DA, Hanahan IK: Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature 2001, 413:311-316.
15. Malyukova A, Dohda T, von der Lehr N, Akhoondi S, Corcoran M, Heyman M, Spruck C, Giardini D, Lendahl U, Sangfelt O. The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. Cancer Res 2007, 67:5611-5616.
16. Park MJ, Taki T, Oda M, Watanabe T, Yumura-Yagi K, Kobayashi R, Suzuki N, Hara J, Honibe K, Hayashi Y. FBXW7 and NOTCH1 mutations in childhood T-cell acute lymphoblastic leukaemia and T-cell non-Hodgkin lymphoma. Br J Haematol 2009, 145:198-205.
17. Kwak EL, Moberg KH, Wahner DC, Quinn JE, Gilmore PM, Graham CA, Hanahan IK, Harkin DP, Haber DA, Bell DW. Infrequent mutations of Archipelago (hAGO, HCD4, Fbw7) in primary ovarian cancer. Gynecol Oncol 2005, 98:124-128.
18. Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, Recht LD, Sikic B. Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Res 2005, 65:8679-8689.
19. Yokobori T, Mimori K, Ivatsuki M, Ishii H, Onyamoa I, Fukagawa T, Kuvano H, Nakayama KI, Mori M. p53-Altered FBW7 expression determines poor prognosis in gastric cancer cases. Cancer Res 2009, 69:3788-3794.
20. Ivatsuki M, Mimori K, Ishii H, Yokobori T, Takatsuno Y, Sato T, Toh H, Onyamoa I, Nakayama KI, Baba H, Mori M. Loss of FBW7, a cell cycle regulating gene, in colorectal cancer: clinical significance. Int J Cancer 2010, 126:1828-1837.
21. Jones PA, Baylin SB. The fundamental role of epigenetic changes in cancer. Nat Rev Genet 2002, 3:415-428.
22. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003, 349:2042-2054.
23. Maier S, Lesche R, Nimmiich M, Eckhardt F, Dahlstroem C, Plum A. DNA methylation markers- an opportunity to further individualize therapy in breast cancer? Personalized Medicine 2005, 1:349-357.
24. Fiegl H, Jones A, Hausser-Kronberger C, Huravetz G, Reitsamer R, Jones RL, Dowsett M, Mueller-Holzner E, Windschigler G, Davenhigler G, Goebel G, Enssinger C, Jacobs I, Widischwender M. Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer. Clin Cancer Res 2008, 14:3494-3502.
25. Verma M, Seminars D, Arena FJ, John C, Ivamotono K, Hartmannel V. Genetic and epigenetic biomarkers in cancer: improving diagnosis, risk assessment, and disease stratification. Mol Diagn Ther 2006, 10:1-15.
26. Spruck C, Sun D, Fiegl H, Marsh C, Mueller-Holzner E, Goebel G, Widischwender M, Reed SI. Detection of low molecular weight derivatives of cyclin E1 is a function of cyclin E1 protein levels in breast cancer. Cancer Res 2006, 66:7355-7360.
27. Bergh J, Norberg T, Spigrosen S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995, 1:1029-1034.
28. Miller LD, Smids J, George J, Vega VR, Vergana L, Pioner A, Pawtxtan Y, Hall P, Kraar S, Liu ET, Bench J. An expression signature for p53 status in
human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci 2005, 102:13550-13555.

29. Sangfelt O, Cepeda D, Malayakova A, van Drogen F, Reed SI. Both SCF (Cdk4/alpha) and SCF(Cdk4alpha) are required for cyclin E turnover in cell lines that do not overexpress cyclin E. Cell Cycle 2008, 7:1075-1082.

30. Zilberman D, Henikoff S. Genome-wide analysis of DNA methylation patterns. Development. 2007, 134:3959-3965.

31. Agrelo R, Cheng WH, Setien F, Ropero S, Espada J, Fraga MF, Hentzen M, Paez MF, Sanchez-Cespedes M, Antiga MJ, Guererro D, Castells A, von Kobbe C, Bohr VA, Esteller M. Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. PNAS 2006, 103:8822-8827.

32. Image J software. [http://rsb.info.nih.gov/ij/]

33. DiNardo DN, Butcher DT, Robinson DP, Archer TK, Rodenhiser DI. Functional analysis of CpG methylation in the BRCA1 promoter region. Oncogene 2001, 20:5331-5340.

34. Widenschwendter M, Siegmund KD, Muller HM, Fiegl H, Marth C, Muller-Holzner E, Jones PA, Laird PW. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 2004, 64:3807-3813.

35. Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O, Reed SI. Human F-box protein protein HSc70 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 2001, 413:516-522.

36. Li J, Pauley AM, Suqiang R, Ruhl AE, Ruble C, Gunney ME. SEL-10 interacts with presin1, facilitates its ubiquitination, and alters A-beta peptide production. J Neurochem 2002, 82:1540-1548.

37. Yamazaki L, Pagano M. Cell cycle, proteolysis and cancer. Curr Opin Cell Biol 2004, 16:623-628.

38. Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 2006, 6:369-381.

39. Sterian A, Kan T, Berk AT. Mutational and LOH analyses of the chromosome 4q region in esophageal adenocarcinoma. Oncology 2006, 70:168-172.

40. Hinks J, Krausz A, Lakshmi B, Navin NE, Riggs M, Leibu E, Esposito D, Alexander J, Troge J, Grubor V, Yoon S, Wigler M, Ye K, Bersenes-Dale AL, Naume B, Schlicting E, Norton L, Hagerstrom T, Skoog L, Auer G, Manner S, Lundin P, Zetterberg A. Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res 2006, 16:1465-1479.

41. Tovey S, Durnee B, Wotton CJ, Forsyth A, Cooke TG, Bartlett JM. Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin Cancer Res 2005, 11:4835-4842.

42. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shok S, Stewart SJ, Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER-2 overexpressing metastatic breast cancer. J Clin Oncol 2002, 20:719-726.

43. Sharma G, Misra S, Yang YH, Panchar S, Hazrah P, Datta Gupta S, Ralhan R. Prognostic relevance of promoter hypermethylation of multiple genes in breast cancer patients. Cell Oncol 2009, 31:487-500.

44. Chiang JW, Koff NJ, Cass L, Baldwin RL. BRCA1 promoter methylation predicts adverse ovarian cancer prognosis. Gynecol Oncol 2006, 101:403-410.

45. Braggio E, Maxiolo A, Gouveia ME, Magalhaes R, Souto Filho JT, Gamaia M, Nucci M, Renault IZ. Methylation status of nine tumor suppressor genes in multiple myeloma. Int J Hematol 2010, 91:87-96.

46. Morris MA, Ricketts C, Gentle D, Abdulkarim M, Clarke N, Brown M, Kishida T, Yao M, Laitf F, Maher ER. Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene 2010, 29:2104-2117.

47. Azarni V, Buzyn A, Le Noir S, Baleydier F, Simon A, Beldjord K, Reman D, Witz F, Fagot T, Tavenier E, Turq P, Lecuyer T, Huguet F, Vernant JP, Daniel F, Béne MC, Ifrah N, Thomas X, Dombret H, Macintyre E. NOTCH1 / FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood 2009, 113:3918-3924.

48. Finkin S, Aylon Y, Anzi S, Oren M, Shaulian E. Fbw7 regulates the activity of endoreplication mediators and the p53 pathway to prevent drug-induced polyplody. Oncogene 2008, 27:4411-4421.

49. Gonzalez-Angulo AM, Hennessy BT, Mills GB. Future of Personalized Medicine in Oncology: A Systems Biology Approach. J Clin Oncol 2010, 28:2777-2783.

50. Jiang H, Reinhardt HC, Bartkova J, Tommasi M, Blomqvist C, Nevanlinna H, Bartek J, Yaffe MB, Hemmann MT. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev 2009, 23:1895-1909.

51. Takao N, Kato H, Mori R, Morrison C, Sonoda E, Sun X, Shimizu H, Yoshikawa T, Sakaeda S, Yamamoto K. Disruption of ATM in p53-null cells causes multiple functional abnormalities in cellular response to ionizing radiation. Oncogene 1999, 18:7002-7009.

52. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtis NJ, Helladay T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917.

53. Mao JH, Kim IJ, Wu D, Climent J, Kang HC, DelRosario R, Balmain A. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science 2008, 321:1499-1502.